午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Antipyretic analgesics>Antipyretic analgesics> Acetaminophen
Acetaminophen
  • Acetaminophen
  • Acetaminophen

Acetaminophen NEW

Price $6 $5 $1
Package 1KG 25KG 100KG
Min. Order: 1KG
Supply Ability: g-kg-tons, free sample is available
Update Time: 2024-03-29

Product Details

Product Name: Acetaminophen CAS No.: 103-90-2
Min. Order: 1KG Purity: 99%
Supply Ability: g-kg-tons, free sample is available Release date: 2024/03/29
Lead time: In stock Packaging: bottle/drum/bucket/IBC, as request.
Delivery: By sea, by air, by express Origin: Manufacturer
Name: Sun

1. Product information

 Names

Nameparacetamol
SynonymMore Synonyms

 4-Acetamidophenol Biological Activity

DescriptionAcetaminophen (paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic drug.
Related Catalog
Signaling Pathways >> Immunology/Inflammation >> COX
Research Areas >> Inflammation/Immunology
Natural Products >> Phenylpropanoids
Target

COX-2:25.8 μM (IC50)

COX-1:113.7 μM (IC50)

Human Endogenous Metabolite

In VitroIn vitro, acetaminophen elicites a 4.4-fold selectivity toward COX-2 inhibition (IC50 113.7 μM for COX-1; IC50 25.8 μM for COX-2). Following oral administration of the drug, maximal ex vivo inhibitions are 56% (COX-1) and 83% (COX-2). Acetaminophen plasma concentrations remaine above the in vitro IC50 for COX-2 for at least 5 h postadministration. Ex vivo IC50 values (COX-1: 105.2 μM; COX-2: 26.3 μM) of acetaminophen compared favorably with its in vitro IC50 values. In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors. However, a >95% COX-1 blockade relevant for suppression of platelet function is not achieved[1]. MTT assay shows that Acetaminophen (APAP) in a dose of 50 mM significantly (p<0.001) reduces cell viability to 61.5±6.65%. Interestingly, the significant (p<0.01) increase in cell viability to 79.7±2.47% is observed in the Acetaminophen/HV110 co-treated cells, compared to Acetaminophen treated cells[2].
In VivoAdministering Acetaminophen (250?mg/kg, orally) to the mice causes significant (p<0.001) liver damage and necrosis of cells as evidenced by the elevated serum hepatic enzymes alanine aminotransferase (ALT), aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (γGT) compared with normal group. Conversely, effects of pretreatment with different doses of citral (125, 250, and 500?mg/kg) exhibited a significant (p<0.05) decrease in serum activities of ALT (91.79%, 93.07%, and 95.61%, resp.), AST (93.40%, 91.89%, and 96.52%, resp.), ALP (39.29%, 37.07%, and 59.80%, resp.), and γGT (92.83%, 91.59%, and 93.0%, resp.), when compared to the Acetaminophen group. Similar results were found in pretreatment with SLM on the activity of ALT (95.90%), AST (95.03%), ALP (70.52%), and γGT (92.69%)[3].
Cell AssayHuman hepatoma cell line HepG2 is cultured in low glucose DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL Penicillin and 100 μg/mL Streptomycin and 2 mM l-glutamine. The cells are maintained in 75 cm2 flasks at 37°C in a humidified atmosphere containing 5% CO2 and split at 80% confluence every 5 days. Cells are seeded in 24-well plate (2×105 cells) and incubated at 37°C overnight followed by cells pretreatment with complete DMEM containing high glucose concentration in order to downregulate autophagy. After 6 h, cells are treated with different concentrations of postbiotics obtained from Lactobacillus fermentum BGHV110 strain (HV110) in order to select appropriate dose for further experiments. Postbiotic is dissolved in complete DMEM medium and added to the cells in specific final concentration. In all other experiments seeded cells are treated with 50 mM Acetaminophen alone or co-treated with 50 mM Acetaminophen and selected dose of lyophilized HV110. To analyze autophagic flux, simultaneously with treatments, cells are exposed to lysosomotropic agent Chloroquine at a concentration of 25 μM, to inhibit autophagosome-lysosome fusion[2].
Animal AdminMice[3] Male Swiss mice (30-40?g) are used. The experimental animals are divided into six groups of five animals each. Firstly, each group receive orally during seven days the following treatment: Group I: the mice do not receive any treatment (normal). Group II: the mice receive citral vehicle (0.1% Tween 80 solution). Groups III-V: the mice are pretreated with citral at doses of 125, 250, and 500?mg/kg, respectively. Group VI: the mice are pretreated with the hepatoprotective standard drug Silymarin (SLM) (200?mg/kg). After this time, the animals fasted for 8?h and then receive oral Acetaminophen on the seventh day at a dose of 250?mg/kg in Groups II-VI. Group I orally receive saline that contained 0.1% Tween 80 solution (Acetaminophen vehicle). The stock solution is used as the first concentration of 50?mg/mL and after that is diluted in 0.1% Tween 80 solution to prepare the solutions of 25 and 12.5?mg/mL. After 12?h of Acetaminophen administration, serum samples and liver tissue are collected followed by biochemistry and histological analysis.
References

[1]. Hinz, B, et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J, 2008. 22(2): p. 383-90.

[2]. Dini? M, et al. Lactobacillus fermentum Postbiotic-induced Autophagy as Potential Approach for Treatment ofAcetaminophen Hepatotoxicity. Front Microbiol. 2017 Apr 6;8:594.

[3]. Uchida NS, et al. Hepatoprotective Effect of Citral on Acetaminophen-Induced Liver Toxicity in Mice. Evid Based Complement Alternat Med. 2017;2017:1796209.

 Chemical & Physical Properties

Density1.3±0.1 g/cm3
Boiling Point387.8±25.0 °C at 760 mmHg
Melting Point168-172 °C(lit.)
Molecular FormulaC8H9NO2
Molecular Weight151.163
Flash Point188.4±23.2 °C
Exact Mass151.063324
PSA49.33000
LogP0.34
Vapour Pressure0.0±0.9 mmHg at 25°C
Index of Refraction1.619
Storage conditionStore at RT
Water Solubility14 g/L (20 oC)

 MSDS

4-Acetamidophenol MSDS(Chinese)

 Toxicological Information

CHEMICAL IDENTIFICATION

  • RTECS NUMBER :

  • AE4200000

  • CHEMICAL NAME :

  • Acetanilide, 4'-hydroxy-

  • CAS REGISTRY NUMBER :

  • 103-90-2

  • BEILSTEIN REFERENCE NO. :

  • 2208089

  • LAST UPDATED :

  • 199806

  • DATA ITEMS CITED :

  • 92

  • MOLECULAR FORMULA :

  • C8-H9-N-O2

  • MOLECULAR WEIGHT :

  • 151.18

  • WISWESSER LINE NOTATION :

  • QR DMV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 591 mg/kg/2D-I

  • TOXIC EFFECTS :

  • Liver - liver function tests impaired Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - aplastic anemia

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 4962 ug/kg

  • TOXIC EFFECTS :

  • Gastrointestinal - changes in structure or function of endocrine pancreas Liver - liver function tests impaired Blood - other changes

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 714 mg/kg

  • TOXIC EFFECTS :

  • Liver - other changes

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - infant

  • DOSE/DURATION :

  • 1440 mg/kg/6D

  • TOXIC EFFECTS :

  • Behavioral - irritability Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - body temperature increase

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human

  • DOSE/DURATION :

  • 143 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - general anesthetic

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 360 mg/kg/2D

  • TOXIC EFFECTS :

  • Gastrointestinal - nausea or vomiting Liver - other changes Skin and Appendages - dermatitis, other (after systemic exposure)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 801 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - general anesthetic Gastrointestinal - nausea or vomiting Liver - other changes

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 714 mg/kg

  • TOXIC EFFECTS :

  • Cardiac - EKG changes not diagnostic of specified effects

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human

  • DOSE/DURATION :

  • 357 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - anorexia (human) Behavioral - coma Gastrointestinal - nausea or vomiting

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 260 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - coma Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 490 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 143 mg/kg/24H-I

  • TOXIC EFFECTS :

  • Behavioral - anorexia (human) Liver - hepatitis (hepatocellular necrosis), zonal Liver - jaundice, other or unclassified

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 650 mg/kg

  • TOXIC EFFECTS :

  • Vascular - BP lowering not characterized in autonomic section Vascular - other changes Nutritional and Gross Metabolic - metabolic acidosis

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 50 mg/kg

  • TOXIC EFFECTS :

  • Cardiac - other changes Lungs, Thorax, or Respiration - acute pulmonary edema Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 400 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - coma Liver - liver function tests impaired Nutritional and Gross Metabolic - metabolic alkalosis

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 1944 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 1205 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - somnolence (general depressed activity) Behavioral - tremor

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 338 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 367 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - analgesia Nutritional and Gross Metabolic - body temperature decrease

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 310 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • 2 gm/kg

  • TOXIC EFFECTS :

  • Behavioral - altered sleep time (including change in righting reflex) Blood - changes in spleen Nutritional and Gross Metabolic - body temperature decrease

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • 826 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - analgesia

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - guinea pig

  • DOSE/DURATION :

  • 2620 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Behavioral - tremor

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Amphibian - frog

  • DOSE/DURATION :

  • 50 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - altered sleep time (including change in righting reflex) Behavioral - ataxia Lungs, Thorax, or Respiration - other changes

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Mammal - species unspecified

  • DOSE/DURATION :

  • 512 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Unreported

  • SPECIES OBSERVED :

  • Mammal - species unspecified

  • DOSE/DURATION :

  • 891 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 105 gm/kg/35D-C

  • TOXIC EFFECTS :

  • Liver - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 68 gm/kg/13W-C

  • TOXIC EFFECTS :

  • Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 6080 mg/kg/19D-I

  • TOXIC EFFECTS :

  • Gastrointestinal - other changes Liver - changes in liver weight Blood - changes in leukocyte (WBC) count

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 1600 mg/kg/2D-I

  • TOXIC EFFECTS :

  • Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - cytochrome oxidases (including oxidative phosphorylation)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 136 gm/kg/13W-C

  • TOXIC EFFECTS :

  • Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 336 gm/kg/40W-C

  • TOXIC EFFECTS :

  • Liver - hepatitis (hepatocellular necrosis), diffuse Liver - other changes Liver - changes in liver weight

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 164 gm/kg/78W-C

  • TOXIC EFFECTS :

  • Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - tumors

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 135 gm/kg/77W-C

  • TOXIC EFFECTS :

  • Tumorigenic - Carcinogenic by RTECS criteria Liver - hepatitis (hepatocellular necrosis), zonal Liver - tumors

  • TYPE OF TEST :

  • TD - Toxic dose (other than lowest)

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 270 gm/kg/77W-C

  • TOXIC EFFECTS :

  • Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Endocrine - other changes

  • TYPE OF TEST :

  • TD - Toxic dose (other than lowest)

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 329 gm/kg/78W-C

  • TOXIC EFFECTS :

  • Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 650 mg/kg

  • SEX/DURATION :

  • female 29 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - Apgar score (human only) Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - other postnatal measures or effects

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 417 mg/kg

  • SEX/DURATION :

  • female 20 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - hepatobiliary system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1300 mg/kg

  • SEX/DURATION :

  • female 31-32 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Effects on Newborn - other neonatal measures or effects

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1500 mg/kg

  • SEX/DURATION :

  • female 8-19 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 12500 mg/kg

  • SEX/DURATION :

  • female 14 day(s) pre-mating female 1-11 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 1 gm/kg

  • SEX/DURATION :

  • female 3 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - other postnatal measures or effects

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 35 gm/kg

  • SEX/DURATION :

  • male 70 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - other effects on male

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 25 mg/kg

  • SEX/DURATION :

  • male 1 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 600 mg/kg

  • SEX/DURATION :

  • male 1 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 2500 mg/kg

  • SEX/DURATION :

  • female 6-15 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 2500 mg/kg

  • SEX/DURATION :

  • female 6-15 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - urogenital system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 2 gm/kg

  • SEX/DURATION :

  • female 1 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Fertility - other measures of fertility

  • TYPE OF TEST :

  • Micronucleus test

  • TYPE OF TEST :

  • Cytogenetic analysis

  • TYPE OF TEST :

  • Sister chromatid exchange

  • TYPE OF TEST :

  • Unscheduled DNA synthesis

  • TYPE OF TEST :

  • Micronucleus test

  • TYPE OF TEST :

  • DNA damage

  • TYPE OF TEST :

  • Unscheduled DNA synthesis

  • TYPE OF TEST :

  • Cytogenetic analysis

  • TYPE OF TEST :

  • Cytogenetic analysis

  • TYPE OF TEST :

  • Sister chromatid exchange

  • TYPE OF TEST :

  • Sex chromosome loss and nondisjunction

MUTATION DATA

  • TYPE OF TEST :

  • Sister chromatid exchange

  • TEST SYSTEM :

  • Rodent - hamster Lung

  • DOSE/DURATION :

  • 1 mmol/L

  • REFERENCE :

  • MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986- Volume(issue)/page/year: 3,51,1988 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 3(3),100,1973 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 12,601,1978 TOXICOLOGY REVIEW NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB282-666 TOXICOLOGY REVIEW OBGNAS Obstetrics and Gynecology. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1953- Volume(issue)/page/year: 58,57S,1981 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80396 No. of Facilities: 1829 (estimated) No. of Industries: 7 No. of Occupations: 14 No. of Employees: 9269 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80396 No. of Facilities: 1261 (estimated) No. of Industries: 7 No. of Occupations: 26 No. of Employees: 65107 (estimated) No. of Female Employees: 56260 (estimated)

 Safety Information

SymbolArticle illustration
GHS07
Signal WordWarning
Hazard StatementsH302-H315-H317-H319
Precautionary StatementsP280-P301 + P312 + P330-P305 + P351 + P338
Personal Protective Equipmentdust mask type N95 (US);Eyeshields;Gloves
Hazard CodesXn
Risk PhrasesR22:Harmful if swallowed. R36/37/38:Irritating to eyes, respiratory system and skin . R52/53:Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R36/38:Irritating to eyes and skin . R40:Limited evidence of a carci
Safety PhrasesS26-S36-S61-S37/39
RIDADRNONH for all modes of transport
WGK Germany1
RTECSAE4200000
HS Code29242930

 Precursor & DownStream

Precursor  0



DownStream  10

Previous 1/3 Next

  • Article illustration CAS#:105326-63-4
    N-[4-(quinolin-...

  • Article illustration CAS#:109690-44-0
    [4-[2-(4-azaniu...

  • Article illustration CAS#:30824-21-6
    4-Acetamidophen...

  • Article illustration CAS#:3273-78-7
    Benzenamine,4,4...

 Customs

HS Code29242930

 Articles524

More Articles
Characterization of a highly sensitive and selective novel trapping reagent, stable isotope labeled glutathione ethyl ester, for the detection of reactive metabolites.

J. Pharmacol. Toxicol. Methods 76 , 83-95, (2015)

Glutathione (GSH) trapping assays are widely used to predict the post-marketing risk for idiosyncratic drug reactions (IDRs) in the pharmaceutical industry. Although several GSH derivatives have been ...

Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.

Sci. Rep. 5 , 8521, (2015)

Overdosing of the analgesic acetaminophen (APAP, paracetamol) is a major cause of acute liver injury. Whereas toxicity is initiated by hepatocyte necrosis, course of disease is regulated by mechanisms...

Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.

J. Chromatogr. Sci. 52(7) , 590-5, (2014)

Methotrexate (MTX) is a dihydrofolate reductase inhibitor that is used for the treatment of tumors and autoimmune diseases. Several automated binding assays are used in clinical practice and numerous ...

 Synonyms

APAP
Calpol
NAPAP
p-acetaminophenol
Panadol
Tylenol
Exdol
Acetamide, N-(4-hydroxyphenyl)-
4-(Acetylamino)phenol
Acetamide, N-(p-hydroxyphenyl)-
Fevor
Acetanilide, 4'-hydroxy-
N-(p-hydroxyphenyl)acetamide
Paracetamol
N-(4-Hydroxy-phenyl)-acetamide
Korum
4-13-00-01091 (Beilstein Handbook Reference)
p-hydroxyacetanilide
G 1
p-Acetylaminophenol
MFCD00002328
Panex
QR DMV1
N-(4-Hydroxyphenyl)acetamide
N-Acetyl-4-aminophenol
EINECS 203-157-5
4'-Hydroxyacetanilide
N-(4-Hydroxyphenyl)acetanilide
Acetaminophen
p-(Acetylamino)phenol
Phenol, p-acetamido-
4-Acetaminophenol
Dirox
4-Acetamidophenol
Dypap
Hedex
N-Acetyl-p-aminophenol


2. Packaging

For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.

For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product. 

                     Or smaller package 1kg/bottle, 10kgs/bottle as request. 


Article illustrationArticle illustration


3. Shipping

Article illustration


4. Contact information

For more details, pls contact us freely.

Email address : Sun@fdachem.com

Mob: 86 13526505137

WhatsApp/Skype/Wechat/LINE: 86 13526505137





Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/1KG
VIP1Y
Forest chemical technology
 2025-01-14
$160.00/1kg
VIP1Y
Guangdong Junhua Chemical Co., Ltd
 2024-12-24
$150.00/1kg
VIP1Y
Hebei Zhuanglai Chemical Trading Co Ltd
 2024-12-03
$41.00/500mg
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
$41.00/500mg
VIP3Y
TargetMol Chemicals Inc.
2024-11-19
$0.00/1KG
VIP3Y
Hebei Weibang Biotechnology Co., Ltd
 2024-10-29
$100.00/25kg
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
 2024-10-28
$20.00/1kg
Shaanxi Franta Biotechnology Co., Ltd
 2024-09-24
$8.00/1kg
VIP3Y
Hebei Dangtong Import and export Co LTD
 2024-09-11
$3.50/200kg
VIP1Y
Aurora Industry Co., Ltd.
 2024-09-05
  • Since: 2023-02-10
  • Address: Room 01, 2288 E05, Building 14, East Henan University, Science and Technology Park, 279 Xisanhuan Ro
INQUIRY